Gilead Sciences (NQ:GILD)

Gilead Sciences to Present at Upcoming Investor Conferences

February 23, 2026

Gilead Sciences is buying Arcellx for $7.8 billion because it sees potential for more than $6 billion in sales for anito-cel by 2029. GILD stock slipped as ACLX soared.

Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗

February 23, 2026

Via Investor's Business Daily

Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗

February 23, 2026

Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.

Via Benzinga

Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals ↗

February 13, 2026

Via Chartmill

Gilead Sciences Inc (NASDAQ:GILD) Posts Strong Q4 Beat but 2026 Outlook Disappoints ↗

February 10, 2026

Via Chartmill

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Via Stocktwits

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Where Gilead Sciences Stands With Analysts ↗

February 20, 2026

Via Benzinga

Peering Into Gilead Sciences Inc's Recent Short Interest ↗

February 19, 2026

Via Benzinga

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

February 17, 2026

Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures....

5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

February 17, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Topics Earnings

3 Hyped Up Stocks We Steer Clear Of

February 15, 2026

Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Topics Economy

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

Via MarketMinute

Topics Artificial Intelligence ETFs Government

3 Overrated Stocks That Concern Us

February 12, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the...

Exploring the top movers within the S&P500 index during today's session. ↗

February 11, 2026

Via Chartmill

GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook

February 11, 2026

Gilead (GILD) Q4 2025 Earnings Call Transcript

Gilead (GILD) Q4 2025 Earnings Call Transcript ↗

February 10, 2026

Via The Motley Fool

Topics Earnings

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance ↗

February 10, 2026

Here's a look at the details inside Gilead Sciences' fourth-quarter earnings report.

Via Benzinga

Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates

February 10, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the...

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light outlook.

Topics Earnings

Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? ↗

February 10, 2026

Via Investor's Business Daily

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

February 10, 2026

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

Should You Buy Gilead Sciences Before Feb. 10? ↗

February 09, 2026

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue?

Via The Motley Fool

Exploring Gilead Sciences's Earnings Expectations ↗

February 09, 2026

Via Benzinga

Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 08, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

Topics Artificial Intelligence World Trade

February 06, 2026